Wick, A., Bähr, O., Schuler, M., Rohrberg, K., Chawla, S. P., Janku, F., . . . Tabatabai, G. (2021). Phase I assessment of safety and therapeutic activity of BAY1436032 in patients with IDH1-mutant solid tumors. Clinical cancer research, 27(10), . https://doi.org/10.1158/1078-0432.CCR-20-4256
Chicago-Zitierstil (17. Ausg.)Wick, Antje, et al. "Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-mutant Solid Tumors." Clinical Cancer Research 27, no. 10 (2021). https://doi.org/10.1158/1078-0432.CCR-20-4256.
MLA-Zitierstil (9. Ausg.)Wick, Antje, et al. "Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-mutant Solid Tumors." Clinical Cancer Research, vol. 27, no. 10, 2021, https://doi.org/10.1158/1078-0432.CCR-20-4256.